Shandong Boan Biotechnology Wins China Approval for Boyoujing Aflibercept Injection
I'm PortAI, I can summarize articles.
Shandong Boan Biotechnology Co. Ltd. has received marketing approval from China's National Medical Products Administration for its aflibercept injection, Boyoujing®, a biosimilar to EYLEA®, for treating nAMD and DME. The company will partner with Ocumension Therapeutics to commercialize the product in Mainland China, marking a significant milestone in expanding ophthalmic treatment access.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments